Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

15.25 2.83

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.77

Max

15.25

Chiffres clés
By Trading Economics
Revenu	-1.4M -14M
BPA	-0.15
Employés	37
EBITDA	312K -12M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+107.49% upside

Dividendes
By Acuity
Prochains Résultats	6 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-199M 1.1B
Ouverture précédente	12.42
Clôture précédente	15.25

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 juil. 2026, 23:52 UTC

U.S. job growth disappoints, reducing Fed rate hike expectations, while global equities rise amid easing U.S.-Iran tensions and stable oil prices.

3 juil. 2026, 23:52 UTC

European equity indices rise as weaker U.S. job growth dampens Fed rate hike expectations, while ECB signals caution amid mixed economic indicators.

3 juil. 2026, 23:52 UTC

Global equity markets rise as U.S. job growth disappoints and European economic indicators show mixed signals, prompting cautious outlook on interest rate hikes.

3 juil. 2026, 23:52 UTC

Asia equity markets rise as U.S. jobs data eases Fed rate hike concerns, boosting sentiment and commodities like gold and oil.

3 juil. 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Awaits Insights Amid World Cup Spending Boost and Economic Uncertainty.

3 juil. 2026, 23:52 UTC

Brazil's Inflation Rate Release on July 10, 2026: Market Eyes Potential Shifts Amid Service Sector Growth and Global Pressures.

3 juil. 2026, 23:41 UTC

Spain's Consumer Confidence Index Holds Steady at 77.7 Amid Geopolitical Tensions and Inflation Concerns

3 juil. 2026, 23:41 UTC

Correlated Moves

Macro News

Bitcoin is gaining ground amid improved sentiment following a weaker U.S. jobs report, which has eased expectations for Federal Reserve interest rate hikes.

3 juil. 2026, 23:31 UTC

Mexico's June 2026 Inflation Rate Release on July 9 Expected Amid Cautious Optimism Over Global Price Trends.

3 juil. 2026, 23:31 UTC

Mexico's Inflation Rate MoM Release on July 9, 2026: Market Anticipates Impact from U.S. Monetary Policy Adjustments and Global Economic Pressures.

3 juil. 2026, 23:22 UTC

U.S. Balance of Trade Report Set for July 7, Anticipating $78.8 Billion Deficit Amid Labor Market Concerns and Global Economic Volatility

3 juil. 2026, 23:22 UTC

U.S. Imports Data Release on July 7, 2026: Analysts Anticipate Cautious Optimism Amid Tariff Influences and Supply Chain Concerns

3 juil. 2026, 23:22 UTC

U.S. Exports Data Release on July 7, 2026, Expected to Show Continued Growth Amid Geopolitical Tensions and Trade Policy Changes

3 juil. 2026, 23:22 UTC

Canada's Trade Balance Expected to Show C$2.4 Billion Surplus Amid Optimism in Export Performance and Market Uncertainty Over U.S. Trade Relations

3 juil. 2026, 23:21 UTC

Correlated Moves

The Russell 2000 Index is trading lower in after-market hours, reflecting a broader market decline linked to disappointing U.S. job growth data.

3 juil. 2026, 23:21 UTC

Correlated Moves

The S&P 500 Index is trading lower in after-market hours, reflecting minimal movement since Friday's close amid weaker U.S. jobs data.

3 juil. 2026, 23:21 UTC

Nasdaq 100 Index declines slightly in after-market trading, remaining flat overall. Recent U.S. nonfarm payrolls report eases interest rate hike concerns.

3 juil. 2026, 23:21 UTC

Correlated Moves

The Dow Jones Index is trading lower in after-market hours, reflecting a weak performance since Friday's close amid disappointing U.S. nonfarm payrolls data.

3 juil. 2026, 23:21 UTC

The FTSE 100 Index is trading lower in after-market hours, with no specific news identified to explain the decline.

3 juil. 2026, 23:11 UTC

Brazil's Retail Sales MoM report on July 8, 2026, signals cautious market sentiment amid recent declines and economic uncertainty.

3 juil. 2026, 23:11 UTC

Correlated Moves

XRP is trading higher, buoyed by positive sentiment in the digital currency market and softer U.S. nonfarm payrolls data impacting interest rate expectations.

3 juil. 2026, 23:11 UTC

Correlated Moves

Macro News

Ethereum is trading higher since Thursday, supported by increased interest in Pepeto and a correlated rise in Bitcoin. Earlier, it pulled back from a session high.

3 juil. 2026, 23:01 UTC

Declining 30-Year Mortgage Rates Signal Potential Boost in U.S. Housing Market Confidence and Activity

3 juil. 2026, 23:01 UTC

Terra is trading higher during Friday's session, maintaining upward momentum since Thursday. No specific news has been identified to explain this price movement.

3 juil. 2026, 23:01 UTC

Cardano is trading higher today, continuing a notable increase since Thursday's close. The asset remains above its 20-day moving average.

3 juil. 2026, 22:51 UTC

Brazil's Central Bank to Release Key Interest Rate Insights Amid Global Economic Influences on July 6, 2026.

3 juil. 2026, 22:51 UTC

Japan's Current Account data release on July 7, 2026, forecasts a JPY 4.1 trillion surplus amid cautious market sentiment and potential currency volatility concerns.

3 juil. 2026, 22:51 UTC

The DAX 30 Index is trading lower in after-market hours, with no specific news identified. Recent U.S. jobs data may be influencing market sentiment.

3 juil. 2026, 22:31 UTC

UK Housing Market Faces Negative Outlook as RICS House Price Balance Forecasts -0.32% Amid Economic Pressures and Inflation Concerns

3 juil. 2026, 22:11 UTC

Japan's Household Spending Data Set for Release Amidst Declining Consumer Confidence and Currency Market Volatility

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

107.49% hausse

Prévisions sur 12 Mois

Moyen 31.6 USD 107.49%

Haut 40 USD

Bas 27 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

5 ratings

Achat

Maintien

Vente

Basé sur 5 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.